Actos News | Bladder Cancer
Actos News
  • India Bans Actos – and the Industry Wonders Why

    In June, the government of India joined those of France and Germany in banning Takeda's flagship diabetic treatment, pioglitazone – better known as Actos, which as been strongly implicated in placing patients at an increased risk of developing bladder cancer. According to a media source in that country, the reason was “the [Indian] Health Ministry’s commitment to a parliamentary committee that it would immediately suspend medicines not allowed for sale in major international markets.”  

    read more
  • Takeda Pays – But Again, Not Much

    Late last month, a Los Angeles jury decided that Takeda executives were in fact aware of the cancer risk from its flagship product, Actos – and ordered the Japanese pharmaceutical giant to pay $6.5 million to plaintiff Jack Cooper and his wife. Cooper's lawyers presented the court with evidence demonstrating that Takeda executives were aware of the risks associated with Actos as far back as 2004 – yet spent the next seven years hiding this information from regulators.

    read more
  • Takeda Responds

    Jack Cooper, a retired communications worker, states that at age sixty-four – prior to being prescribed the diabetic drug Actos – he was in good health and looking forward to many more years with his wife of nearly fifty years and his grandchildren.

    read more
  • Oh, How The Mighty Have Fallen!

    Just two years ago, Takeda Pharmaceuticals' Actos (dabigatran) was the top-selling diabetic drug in the world. With over $4.5 billion in sales, it accounted for 27% of the company's revenue.

    Today, the drug has been been implicated in the development of bladder cancer. It has been pulled from pharmacy shelves in the E.U. and is under increasing scrutiny by the U.S. Food and Drug Administration (FDA).  The British Medical Journal (BMJ) recently published a study which demonstrated an increasing risk of developing bladder cancer with long-term use.

    read more
  • Takeda Finally Taken to Task

    Several law firms across the country have issued press releases across the Internet with the news many bladder cancer victims have been waiting for. The first trial involving Takeda Pharmaceuticals and their allegedly-defective diabetic drug, Actos, will commence on 19 February, 2013.

    The case involves one Jack Cooper and other  parties, and will be overseen by the Honorable Judge Kenneth R. Freeman.

    read more